Upgrade to SI Premium - Free Trial

MKM Partners Slighly Increases Amarin (AMRN) Vascepa Estimates Post Q1

May 10, 2013 11:28 AM
MKM Partners reiterated its Buy rating and $12 price target on Amarin Corporation (NASDAQ: AMRN) and slightly increased Vacepa estimates ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments Analyst EPS Change Analyst EPS View

Next Articles